Search results for " hepatitis"

showing 10 items of 546 documents

Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated ampli…

2007

Monitoring of HCV-RNA in blood during antiviral therapy is performed mostly by commercially available reverse transcription polymerase chain reaction-based (RT-PCR) assays, with a lower detection limit of 30-50 IU/mL of HCV-RNA. Use of different tests in the pivotal trials of combination therapy has generated some discordance, in terms of predictive value of the early virological response (EVR). To evaluate whether the use of a more sensitive test, as a qualitative assay based on transcription mediated amplification (TMA) with a lower detection limit of 5-10 IU/mL of HCV-RNA, may obtain a better prediction of EVR and of the ultimate virological outcome, we retrospectively evaluated serial s…

Malemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/09 - Medicina InternaCombination therapyGenotypeTranscription GeneticTranscription-mediated amplificationHepacivirusAlpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsSensitivity and Specificityantiviral therapy EVR HCV chronic hepatitis HCV-RNA RT-PCR TMAPolyethylene Glycolschemistry.chemical_compoundInterferonPredictive Value of TestsVirologyInternal medicineRibavirinmedicineHumansRetrospective StudiesSettore MED/12 - GastroenterologiaHepatologybiologybusiness.industryReverse Transcriptase Polymerase Chain ReactionRibavirinInterferon-alphaNucleic acid amplification techniqueHepatitis C Chronicbiology.organism_classificationVirologydigestive system diseasesRecombinant ProteinsInfectious DiseasesReal-time polymerase chain reactionTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessNucleic Acid Amplification Techniquesmedicine.drug
researchProduct

Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Ev…

2021

Background: Chronic hepatitis C (CHC) is associated with hepatic steatosis, related to both a direct viral action and metabolic features. Vice-versa data on hepatic steatosis after viral eradication by direct-acting antiviral agents (DAA) are undefined although the presence of metabolic alterations could strongly influence the occurrence of steatosis as in NAFLD. The controlled attenuation parameter (CAP) (FibroscanⓇ) allows the qualitative and quantitative evaluation of fatty liver. Aim: to evaluate in patients with CHC whether hepatic steatosis diagnosed by CAP modifies after DAAs-induced sustained virologic response (SVR). Methods: Data were collected the day of DAAs therapy starting and…

Malemedicine.medical_specialtySustained Virologic ResponseOverweightGastroenterologyAntiviral Agents03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicineGenotypemedicineHumansDe novo steatosiDAAAgedRetrospective StudiesHypertriglyceridemiaHepatologybusiness.industryFatty liverHypertriglyceridemiaGastroenterologyAntiviral therapyOverweightHepatitis C ChronicMiddle Agedmedicine.diseaseMale sexFatty LiverSVR.Italy030220 oncology & carcinogenesisHCV030211 gastroenterology & hepatologyFemalemedicine.symptomSteatosisbusinessDirect actingDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Phylogenetic Analysis of isolates from new cases of HBV infection in Southern Italy.

2012

The level of endemicity of hepatitis B virus (HBV) infections in Italy is low and genotype D infections predominant. New HBV strains may however be introduced as a result of movements of people from regions of high endemicity. The aim of the present study was to determine whether strains from new cases of acute hepatitis B detected in southern Italy were due to endemic or new HBV strains. We studied 34 isolates from patients with acute hepatitis B infection, and 35 from chronic hepatitis B patients. A phylogenetic analysis of preS/S region was done by comparing the sequences from the acute and chronic cases with references sequences. The study showed that 44% of strain from acute hepatitis …

Microbiology (medical)AdultMalemedicine.medical_specialtyHepatitis B virusSettore MED/07 - Microbiologia E Microbiologia ClinicaGenotypeBiologymedicine.disease_causeMicrobiologyLiver diseaseEpidemiologyGenotypeGeneticsmedicineHumansMolecular BiologyEcology Evolution Behavior and SystematicsPhylogenyAgedHepatitis B virusAged 80 and overMolecular EpidemiologySettore MED/12 - GastroenterologiaMolecular epidemiologyPhylogenetic treeSequence Analysis DNAHepatitis BMiddle Agedmedicine.diseaseHepatitis BVirologyInfectious DiseasesItalyImmunologyDNA ViralFemaleViral hepatitisHBV genotypes molecular epidemiology Acute HBV infection phylogenetic analysis
researchProduct

Molecular Epidemiology and Evolution in an Outbreak of Fulminant Hepatitis B Virus

2006

ABSTRACT In order to establish the transmission pathway for two outbreak patients affected by fulminant hepatitis B (FHB) following a shared period of hospitalization, we sequenced the complete genomes of the hepatitis B viruses (HBV) isolated from them as well as from the suspected common source and 11 additional controls. Phylogenetic and statistical analyses of these sequences revealed that the two FHB patients were indeed infected by a common source and that the fatal development of the disease did not appear to be associated with any mutation previously reported to be related to FHB. These data have also allowed us to estimate the extent and distribution of genetic variability along th…

Microbiology (medical)Hepatitis B virusGenome Viralmedicine.disease_causeDisease OutbreaksEvolution MolecularOrthohepadnavirusVirologymedicineHumansFulminant hepatitisLetter to the EditorPhylogenyGeneticsHepatitis B virusMolecular EpidemiologybiologyMolecular epidemiologyTransmission (medicine)OutbreakSequence Analysis DNAHepatitis BHepatitis Bbiology.organism_classificationmedicine.diseaseVirologyHepadnaviridaeDNA ViralJournal of Clinical Microbiology
researchProduct

Antibodies to hepatitis B virus x-protein in sera of patients with acute and chronic acitve hepatitis

1989

Sera of patients with acute (AH) and chronic active hepatitis (CAH) were tested for anti-hepatitis B virus (HBV) x-protein (HBx) by immunoblotting, using recombinant MS2- and beta gal-HBx fusion proteins as substrate. Antibodies against HBx were detected in 5 out of 17 patients with AH at an early stage of infection, and in 13 out of 35 patients with CAH. Positive sera from AH patients showed a relatively weak anti-HBx reactivity when compared to sera from CAH patients. In follow up studies we tested serial serum samples from patients positive for anti-HBx. Patients with AH were observed for 3 to 6 weeks and CAH patients for up to 51 months. In general anti-HBx reactivities appeared to be s…

Microbiology (medical)Hepatitis B virusmedicine.medical_specialtyRecombinant Fusion ProteinsvirusesBlotting WesternImmunologyViruslaw.inventionViral ProteinsMedical microbiologylawmedicineHumansImmunology and AllergyHepatitis B AntibodiesTransaminasesHepatitis ChronicHepatitisbiologybusiness.industryGeneral MedicineHepatitis Bmedicine.diseasedigestive system diseasesHBxImmunologybiology.proteinRecombinant DNAViral diseaseAntibodyViral hepatitisbusinessMedical Microbiology and Immunology
researchProduct

The role of positive selection in hepatitis C virus

2008

Hepatitis C virus (HCV) is a major health problem worldwide, infecting an estimated 170 million people. In this study, we have employed a large data set of sequences (14,654 sequences from between 25 and 100 clone sequences per analyzed region and per patient) from 67 patients infected with HCV genotype 1 (23 subtype 1a and 44 subtype 1b). For all patients, a sample prior to combined therapy with alpha interferon plus ribavirin was available, whereas for some patients additional samples after 6 or 12 months of treatment were also available. Twenty-seven patients responded to treatment (12 subtype 1a and 15 subtype 1b) and forty patients did not respond to treatment (11 subtype 1a vs. 29 sub…

Microbiology (medical)Hepatitis C virusAlpha interferonHepacivirusViral Nonstructural ProteinsBiologymedicine.disease_causeMicrobiologyCohort Studieschemistry.chemical_compoundViral Envelope ProteinsSequence Analysis ProteinInterferonDrug Resistance ViralRibavirinGeneticsmedicineHumansAmino Acid SequenceSelection GeneticNS5AMolecular BiologyEcology Evolution Behavior and SystematicsChi-Square DistributionRibavirinInterferon-alphaHepatitis Cmedicine.diseaseComplementarity Determining RegionsHepatitis CVirologyHypervariable regionInfectious DiseaseschemistryImmunologyViral hepatitismedicine.drugInfection, Genetics and Evolution
researchProduct

Chronic hepatitis B: who to treat and which choice of treatment?

2009

The goal of antiviral therapy in patients with chronic hepatitis B is to prevent, through persistent suppression of HBV replication, cirrhosis and hepatocellular carcinoma. Currently, seven drugs are available: IFN-alpha, pegylated interferon, lamivudine, adefovir dipivoxil, entecavir, telbivudine and tenofovir. The choice of the drugs should always take into consideration the clinical features of patients, the antiviral efficacy of each drug, the risk of developing resistance, the long-term safety profile, the method of administration and the cost of therapy. Ideal candidates for treatment are hepatitis B e antigen-positive patients with a prolonged phase of immune clearance and hepatitis …

Microbiology (medical)Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularmedicine.disease_causeVirus ReplicationMicrobiologyGastroenterologyAntiviral AgentsDrug Administration ScheduleHepatitis B ChronicPegylated interferonVirologyTelbivudineInternal medicineDrug Resistance ViralmedicineAdefovirHumansRandomized Controlled Trials as TopicHepatitis B virusbusiness.industryNucleotidesLamivudineNucleosidesEntecavirHepatitis Bmedicine.diseaseVirologyInfectious DiseasesPractice Guidelines as TopicHepatitia BbusinessViral hepatitisantiviral Therapymedicine.drugExpert review of anti-infective therapy
researchProduct

Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?

2017

International audience

Microbiology (medical)MESH: Antiviral AgentsMESH: Hepatitis B ChronicMEDLINEMESH: Hepatitis B Core AntigensAntiviral Agents03 medical and health sciences0302 clinical medicineHepatitis B ChronicmedicineHumansHepatitis B Vaccines030212 general & internal medicineHepatitis B AntibodiesMESH: Hepatitis B AntibodiesMESH: Hepatitis B VaccinesMESH: Humansbusiness.industryHepatitis Bmedicine.diseaseVirologyHepatitis B Core AntigensHepatitis b core antibodyMESH: DNA ViralInfectious Diseases[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieImmunologyDNA Viral030211 gastroenterology & hepatology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct

Epidemiology and molecular investigation of hepatitis C infection following holiday haemodialysis

2012

Background: Hepatitis C virus infection (HCV) is not infrequent among haemodialysis patients. Most published reports suggest that patient-to-patient spread, either directly or indirectly, is the most common mode of transmission in renal units. Aim: To investigate the source of an outbreak, and the route of transmission, of acute HCV infection in two Scottish patients occurring within eight weeks of receiving haemodialysis in the same unit while on holiday in Majorca. Methods: This was an international epidemiological and molecular investigation of HCV infection among a cohort of haemodialysis patients from nine countries. Findings: No further HCV-positive infections were observed among resi…

Microbiology (medical)Pediatricsmedicine.medical_specialtyGenotypeHepatitis C virusHepacivirusmedicine.disease_causeDisease OutbreaksHealthcare worker to patientNosocomial transmissionRenal DialysisEpidemiologymedicineHumansIntensive care medicineHolidaysCross InfectionMolecular EpidemiologyMolecular epidemiologyTransmission (medicine)business.industryOutbreakGeneral MedicineHepatitis Cmedicine.diseaseHepatitis CHaemodialysisInfectious DiseasesScotlandSpainCohortRNA ViralbusinessViral hepatitisJournal of Hospital Infection
researchProduct

Chronic hepatitis C infection and insulin resistance: two best friends.

2011

Approximately 170 million people worldwide are chronically infected by HCV, which can result in progressive hepatic injury and fibrosis, culminating in cirrhosis and end-stage liver disease. Among ...

Microbiology (medical)medicine.medical_specialtyCirrhosisbusiness.industryfood and beveragesHepacivirusHCV insulin resistanceHepatitis C Chronicmedicine.diseaseMicrobiologyGastroenterologyFatty LiverLiver diseaseInfectious DiseasesInsulin resistanceChronic hepatitisLiver steatosisFibrosisVirologyInternal medicinemedicineHumansInsulin Resistancebusiness
researchProduct